

1 ORIGINAL RESEARCH

2 Manami Watahiki et al

3 **Comparing the heart–thigh and thigh–ankle arteries with**
4 **the heart–ankle arterial segment for arterial stiffness**
5 **measurements**

6 Running title: Impact of segmental arterial stiffness

7 Manami Watahiki¹

8 Shigeo Horinaka¹

9 Toshihiko Ishimitsu²

10 Shigeru Toyoda¹

11 Teruo Inoue¹

12

13 ¹Department of Cardiovascular Medicine, Dokkyo Medical University, Mibu, Japan; ²Department of

14 Kidney and Hypertension, Dokkyo Medical University, Mibu, Japan

15

16 Correspondence: Shigeo Horinaka

17 Department of Cardiovascular Medicine, Dokkyo Medical University, 880 Kitakobayashi, Mibu,

18 Shimotsuga, Tochigi, Japan, 321-0293

19 Email horinaka@dokkyomed.ac.jp

20

21 **Abstract:**

22 **Purpose:** The cardio-ankle vascular index, applying the stiffness parameter β theory, was

23 calculated using the pulse wave velocity and blood pressure from the aortic orifice to ankle.

24 Accordingly, the impact of the stiffness of the aorta [heart–thigh β (htBETA)] and medium-sized

25 muscular artery [thigh–ankle β (taBETA)] on the stiffness of the heart–ankle β (haBETA) was
26 investigated; further, whether the htBETA (haBETA – taBETA) improved the power of diagnosis of
27 coronary artery disease (CAD) was examined.

28 **Patients and methods:** Segmental β s were calculated using VaSela (Fukuda Denshi, Tokyo) with
29 an additional thigh cuff and compared using the receiver operating characteristic (ROC) curve
30 analysis to evaluate CAD.

31 **Results:** Overall, 90 healthy subjects and 41 patients with CAD were included. In both groups,
32 haBETA and htBETA, but not taBETA, correlated with age, and taBETA was three times higher
33 than htBETA ($p < 0.01$). Multiple regression analysis revealed that haBETA can be estimated using
34 htBETA and taBETA in healthy subjects and patients with CAD ($r = 0.86$, $r = 0.67$, respectively, $p <$
35 0.01), and two-thirds of the haBETA components can be estimated by htBETA using the component
36 analysis. The area under the ROC curve (AUC) for CAD in taBETA (0.493, $p = \text{n.s.}$) was smaller
37 than that in haBETA (0.731, $p < 0.01$) or htBETA (0.757, $p < 0.01$); no difference was observed in
38 AUC between haBETA and htBETA.

39 **Conclusion:** The stiffness of medium-sized muscular arteries of the age-independent thigh–ankle
40 segment (taBETA) was constant, which was three times greater than that of the elastic artery of the
41 heart–thigh artery (htBETA). Two-thirds of the haBETA components could be estimated using
42 htBETA. The ROC curve analysis revealed that the AUC of haBETA could be replaced by that of
43 htBETA, prolonging the measurement segment without affecting the diagnostic power for CAD.

44 **Keywords:** Arterial stiffness, Stiffness parameter, Cardio-ankle vascular index, Coronary artery
45 disease

46 Introduction

47 Carotid–femoral pulse wave velocity (cfPWV) is typically considered the most simple,
48 noninvasive, and popular method to determine arterial stiffness worldwide, as evidenced by the
49 epidemiological studies that have demonstrated its predictive value for cardiovascular events.^{1,2} By
50 contrast, PWV measured outside the aortic trunk at the limb (from femoral to posterior tibial arteries)

51 has no predictive value for end-stage renal disease.³ Therefore, cfPWV is considered the gold
52 standard for arterial stiffness measurement because most elastic arteries are located here.⁴
53 However, PWV is intrinsically pressure dependent considering that arterial compliance (dV/dP)
54 decreases with increasing pressure owing to the curvilinear relationship between arterial pressure
55 and volume and volume (V) increases with increasing pressure, thereby directly increasing PWV, as
56 shown in the Bramwell–Hill derived equation.⁵

57 For incompressible blood in a compressible elastic artery,

$$58 \quad PWV = \sqrt{V \cdot dP / \rho \cdot dV}$$

59 where PWV is in cm/s, V (cm³) is the volume per unit length, P (dyne/cm²) is the pressure, and ρ
60 (g/cm³) is the blood density.

61 Spronk et al⁶ demonstrated that short-term changes in local carotid PWV—calculated based on the
62 relationship between echo-acquired cross-sectional area and tonometric blood pressure
63 measurement—that are concurrent with a decrease in blood pressure can be deemed blood
64 pressure dependent at a rate of approximately 1 m/s per 10 mmHg diastolic blood pressure. To
65 overcome this limitation, the cardio-ankle vascular index (CAVI) is used considering that it is less
66 pressure dependent and derived from stiffness parameter β ,⁷ which is calculated based on the
67 blood pressure and PWV⁸ as follows:

$$68 \quad CAVI = a((\ln(Ps/Pd) \cdot 2\rho/\Delta P) \cdot PWV^2) + b$$

69 where a and b are coefficients,⁹ Ps (dyne/cm²) is the systolic blood pressure, Pd is the diastolic
70 blood pressure, ΔP is Ps – Pd, ρ (g/cm³) is the density of the blood, and PWV (cm/s) is measured
71 by the transient time from the aortic orifice to the ankle. However, the main issue associated with
72 CAVI is that it is calculated from PWV, including the measurement segment of the lower limb (from
73 femoral to posterior tibial arteries), which has no predictive value.³ In clinical practice, CAVI has
74 widely been used as a surrogate arteriosclerosis maker,¹⁰ and this equation includes the
75 coefficients “a” and “b” to adjust it to the value of Hasegawa’s PWV, which is compensated for 80
76 mmHg of diastolic pressure.¹¹ Recently, Takahashi et al⁹ demonstrated that CAVI can interpret

77 heart–ankle β (haBETA) in epidemiological and clinical studies; it can be considered that application
78 of CAVI without the coefficients “a” and “b” is more reasonable in various arterial segments.
79 Therefore, the segmental stiffness parameter β was applied to compare the clinical and
80 physiological implications in the present study using an additional thigh cuff. Although cfPWV can
81 be measured using a thigh cuff,^{12,13} to the best of our knowledge, only one study has analyzed the
82 segmental β as heart–thigh β (htBETA) and thigh–ankle β (taBETA) separately, which was mainly
83 evaluated as an acute effect of nitroglycerin.¹⁴
84 The present study aimed to compare the clinical and physiological implications between the
85 stiffness of elastic aortic arteries (htBETA) and medium-sized limb muscular arteries (taBETA) and
86 to investigate the effects of htBETA and taBETA on haBETA as well as evaluate whether diagnostic
87 power for coronary artery disease (CAD) differed between haBETA and htBETA.

88 **Material and methods**

89 ***Healthy subject and patient selection***

90 Community residents and employees of companies and governments who underwent a periodic
91 health examination from April 2015 to March 2016 in Sano City, Tochigi Prefecture, Japan, were
92 included in the study. Informed consent was obtained from all participants. The study design was
93 approved by the ethics community of the Sano Medical Association Hospital, and data were
94 collected from the database of this institution. The details of data collection and definition have
95 previously been reported,¹⁵ and data regarding current medications, including antihypertensive,
96 hypoglycemic, and hypolipidemic drugs, were collected via a questionnaire. The study protocol was
97 approved by the ethics committee of Dokkyo Medical University according to the Declaration of
98 Helsinki.
99 Patients were referred to Dokkyo Medical University Hospital from April 2015 to March 2016 to
100 undergo their first coronary angiography. All patients who underwent coronary angiography
101 presented with chest pain and exhibited at least 75% stenosis of the proximal left anterior

102 descending or right coronary artery on coronary angiography. The therapeutic goals for patients
103 with suspicious CAD for primary prevention were as follows: systolic and diastolic blood pressure of
104 <130/85 mmHg, fasting blood glucose level of <129 mg/dL, glyated hemoglobin (HbA_{1c}) level of
105 <6.9%, serum low-density lipoprotein (LDL) cholesterol level of <100 mg/dL, high-density lipoprotein
106 (HDL) cholesterol level of >40 mg/dL, and triglyceride level of <150 mg/dL. Written informed
107 consent was obtained from all patients after the study protocol approval from the Institutional
108 Review Board of Dokkyo Medical University. Participants with acute coronary syndrome, distinct
109 aortic aneurysm, arteriosclerosis obliterans (ankle–brachial index, $\leq 0.90^{16}$), and atrial fibrillation
110 were excluded.

111 According to our previous data,¹⁷ the area under the curve (AUC) of CAVI, instead of segmental β ,
112 which has not been reported in single coronary vessel disease, was 0.648; the type I error rate was
113 0.05 in the one-side test, and the type II error rate was ≤ 0.15 (power $\geq 85\%$ power). The number of
114 healthy subjects was two times as that of patients with CAD, and with 5% attrition, it was
115 determined that 81 healthy subjects and 41 patients with CAD were required to detect for
116 equivalence or difference in diagnostic accuracy using the receiver operating characteristic (ROC)
117 curve analysis.¹⁸ For exclusion owing to CAD complications, such as ischemic electrocardiographic
118 change in healthy subjects, a larger sample size was used to ensure the necessary number of
119 healthy subjects. Ultimately, 90 healthy subjects and 41 patients with CAD who agreed to
120 participate were included in the study.

121 ***BETA measurement***

122 To measure the volume change of the femoral artery in the inguinal area, a prototype of the thigh
123 cuff that can be used for volume plethysmography was produced in collaboration with Fukuda
124 Denshi, as shown in Supplementary File 1. The local volume change was accurately reflected when
125 the cuff was wrapped around both thighs at a shorter distance of approximately 20 mm than the
126 thigh circumference in the supine position.

127 The vascular length from the aortic valve to the thigh was calculated as the total distance from the
128 second intercostal space of the parasternal position to the femoral artery in the inguinal area (Lpf) ×
129 1.3, defined as AF¹⁹, and the measured length from the femoral artery in the inguinal area to the
130 middle of the thigh cuff (L1), ie, AF + L1. Moreover, the vascular length from the thigh to the ankle
131 was measured from the middle of the thigh cuff to the middle of the ankle cuff (L2). Thereafter, the
132 vascular length from the aortic valve to the ankle was calculated as follows: AF + L1 + L2.

133 Considering the difficulty in determining the transient time from the aortic valve to the brachial from
134 the valve opening sound, the time is determined based on the time between the aortic valve closing
135 sound (IIA) of the phonocardiogram and notch of the brachial pulse wave (dicrotic notch). Therefore,
136 the traveling time of heart–thigh (Tht), thigh–ankle (Tta), and heart–ankle (Tha) was automatically
137 calculated using the VS-1500 vascular screening system (Fukuda Denshi Co., Tokyo, Japan).

138 PWV was calculated by dividing the vascular length by the traveling time and was recorded in the
139 comma-separated value format as follows:

140 $htPWV = (AF + L1)/Tht$

141 $taPWV = L2/Tta$

142 $haPWV = (AF + L1 + L2)/ Tha$

143 Using the original CAVI formula⁸ and removing the coefficient values of a and b,⁹ segmental β was
144 calculated as follows:¹⁴

145 $Segmental \beta = \ln (Ps/Pd) \times 2\rho/\Delta P \times PWV^2$

146 where Ps and Pd are the systolic and diastolic blood pressures, respectively, $\Delta P = Ps - PD$, ρ is the
147 blood density, and PWV is the value calculated for each segment.

148 Accordingly, the following were determined:

149 $htBETA = \ln (Ps/Pd) \times 2\rho/\Delta P \times htPWV^2$

150 $taBETA = \ln (Ps/Pd) \times 2\rho/\Delta P \times taPWV^2$

151 $haBETA = \ln (Ps/Pd) \times 2\rho/\Delta P \times haPWV^2$

152 First, to clarify the characteristics of htBETA, taBETA, and haBETA, their correlation was evaluated,
153 and their relationship with the clinical characteristics was examined in healthy subjects and patients

154 with CAD who underwent arterial stiffness measurements using volume plethysmography ten
155 minutes before coronary angiography in the catheter laboratory. Thereafter, we compared htBETA,
156 taBETA, and haBETA between healthy subjects and patients with CAD to determine the superior
157 index for discerning the presence of CAD.

158 ***Statistical analysis***

159 Results were presented as mean ± standard deviation for continuous data and as numbers and
160 percentages for categorical data. Data were compared using Student's *t*-test or analysis of variance
161 for continuous variables and using chi-square test for categorical variables. Correlation coefficients
162 were calculated for paired data. Furthermore, multiple regression analysis was performed, and
163 principal component analysis was conducted.

164 ROC curves were used to visualize the sensitivity and specificity depending on the threshold. AUC
165 and its standard error (SE) were obtained. The statistical comparison of the areas under two ROC
166 curves was derived by the method described by Hanley and McNeil,²⁰ who demonstrated that the
167 difference in AUC of two ROC curves derived from the same set of patients can be determined to
168 be random or real from the critical ratio *Z*, which is defined as follows:

$$169 \quad Z = \frac{A1 - A2}{\sqrt{SE1^2 + SE2^2 + 2rSE1 \times SE2}}$$

170 where *A1* and *SE1* are the observed area and estimated SE of AUC associated with test 1,
171 respectively; *A2* and *SE2* refer to the corresponding quantities for test 2. In addition, *r* was derived
172 from $(A1 + A2)/2$ and $(r_n + r_a)/2$, wherein *r_n* and *r_a* are correlation coefficients between measurement
173 values of tests 1 and 2 in the control groups and those of tests 1 and 2 in the diseased groups,
174 respectively. Then, the obtained *Z* value was above the cutoff value, it was referred to the table of
175 the normal distribution, which was considered as evidence that the AUC was truly different.
176 A P-value of <0.05 was considered statistically significant. All calculations were performed using
177 JMP version 10.0 (SAS Institute, Cary, NC, USA).

178 **Results**

179 ***Baseline characteristics and treatments***

180 Overall, 90 healthy subjects and 41 patients with CAD were included in this study. The healthy
181 subjects were 10 years younger than the patients with CAD [mean age, 54.0 (range, 23–84) and
182 64.1 (range 46–86) years, respectively]. Table 1 shows that patients with CAD were more frequently
183 men and obese. Although antihypertensive and hypoglycemic drugs were more frequently used in
184 patients with CAD than in healthy subjects, systolic and diastolic blood pressures and serum
185 glucose and HbA_{1c} levels remained high (Table 1). By contrast, serum total cholesterol and LDL
186 cholesterol levels were lower and HDL cholesterol level was higher in patients with CAD who were
187 more frequently treated with the hypolipidemic drugs compared with the healthy subjects (Table 1).

188 ***Relationship among htBETA, taBETA, and haBETA in healthy*** 189 ***subjects and patients with CAD***

190 HaBETA was correlated with htBETA ($r = 0.78, p < 0.01$) and taBETA ($r = 0.46, p < 0.01$) in healthy
191 subjects (Figure 1). In patients with CAD, haBETA was correlated only with htBETA ($r = 0.56, p <$
192 0.01 , Figure 2). Moreover, htBETA and taBETA were unrelated in healthy subjects and patients with
193 CAD (Figures 1 and 2).

194 Multiple regression analysis revealed that haBETA can be estimated using htBETA and ta htBETA
195 in healthy subjects ($\text{haBETA} = 0.828 \text{ htBETA} + 0.094 \text{ taBETA} + 1.406, r = 0.86, p < 0.01$, Figure 3)
196 and patients with CAD ($\text{haBETA} = 0.546 \text{ htBETA} + 0.073 \text{ taBETA} + 4.259, r = 0.67, p < 0.01$, Figure
197 4). Moreover, principal component analysis indicated that the plots were horizontally distributed for
198 healthy subjects, whereas the plots were equally distributed in horizontal and vertical directions for
199 patients with CAD (Figure 3). The proportions of variance of htBETA and taBETA to haBETA were
200 65.4% (component 1, relationship between htBETA and haBETA) and 29.7% (component 2,

201 relationship between taBETA and haBETA) in healthy subjects and 52.7% (component 1) and
202 37.2% (component 2) in patients with CAD (Figure 3).
203 These data suggested that compared with patients with CAD, healthy subjects had a greater effect
204 on the variance of htBETA to haBETA.

205 ***Relationship between htBETA, taBETA, haBETA, and clinical*** 206 ***characteristics in healthy subjects and patients with CAD***

207 Table 2 shows that the thigh circumference, height, and body weight were not related to all
208 segmental β s. In healthy subjects and patients with CAD, age was correlated with haBETA ($r =$
209 0.626 and $r = 0.387$, respectively) and htBETA ($r = 0.560$ and $r = 0.406$, respectively) but not
210 taBETA ($p < 0.01$). Systolic and diastolic blood pressures were significantly correlated with taBETA
211 in healthy subjects ($r = 0.338$, $p < 0.01$, and $r = 0.273$, $p < 0.05$, respectively) and patients with CAD
212 ($r = 0.361$, $p < 0.05$, and $r = 0.395$, $p < 0.05$, respectively). Moreover, in healthy subjects, systolic (r
213 $= 0.331$, $p < 0.01$) and diastolic ($r = 0.224$, $p < 0.05$) blood pressures were correlated with haBETA
214 and only the systolic blood pressure was correlated with htBETA ($r = 0.297$, $p < 0.01$). In patients
215 with CAD, the body mass index was correlated with haBETA ($r = 0.372$, $p < 0.05$) and heart rate
216 was correlated with htBETA ($r = 0.366$, $p < 0.05$).
217 In summary, haBETA and htBETA were significantly related to age, whereas taBETA was
218 associated with systolic and diastolic blood pressures.

219 ***Comparison of htBETA, taBETA, and haBETA between healthy*** 220 ***subjects and patients with CAD***

221 As shown in Figure 4, taBETA was three times higher than htBETA in healthy subjects and patients
222 with CAD ($p < 0.01$). Moreover, haBETA and htBETA were significantly lower in healthy subjects
223 compared with those in patients with CAD ($p < 0.01$). However, taBETA did not differ between the
224 two groups.

225 ***ROC curve of haBETA, htBETA, and taBETA in diagnosis of CAD***

226 The ROC curves of haBETA, htBETA, and taBETA in the diagnosis of CAD were computed (Figure
227 5), and the ROC curves of haBETA and htBETA were more upward and shifted to the left side
228 compared with that of taBETA. The AUC \pm SE value of haBETA (0.731 ± 0.046) and htBETA (0.757
229 ± 0.043) was significantly higher than that of taBETA (0.493 ± 0.054) ($p < 0.01$, respectively),
230 although that of haBETA did not differ with that of htBETA ($p = 0.49$). Therefore, haBETA and
231 htBETA were superior to taBETA in discerning the presence of CAD, because taBETA exhibited no
232 discerning ability.

233 ***Diagnostic power for CAD with a threshold of haBETA, htBETA,*** 234 ***and taBETA***

235 To determine the optimal threshold for discerning the presence of CAD, the optimal intersection
236 point between sensitivity and 1-specificity curves of haBETA, htBETA, and taBETA in CAD was
237 computed. The optimal cutoff points were 9.20, 7.72, and 21.0 for haBETA, htBETA, and taBETA,
238 respectively (Figure 5). Using the threshold of 9.20 in haBETA, 7.72 in htBETA, and 21.0 in taBETA,
239 sensitivity of 80.5%, 75.6%, and 65.9% and specificity of 63.3%, 68.9%, and 45.6%, respectively,
240 were obtained (arrows indicate each threshold in Figure 5). Therefore, sensitivity and specificity for
241 discerning the presence of CAD were higher in haBETA and htBETA than in taBETA. However,
242 haBETA and htBETA were not significant ($p = 0.49$).

243 **Discussion**

244 The present study demonstrated that segmental β s, such as htBETA and taBETA, were different. In
245 the healthy subjects and patients with CAD, htBETA was age dependent but taBETA was not
246 (Table 2). Moreover, taBETA was three times higher than htBETA in healthy subjects as well as
247 patients with CAD, suggesting that the stiffness of the medium-sized extremity muscle artery from
248 the thigh–ankle artery was significantly higher than that of the elastic artery in the aorta and that the

249 muscle artery was independent of age. Nichols et al²¹ suggested that stiffness of elastic arteries
250 increased with age, which has primarily been attributed to the degeneration of the medial layer of
251 the arterial walls. By contrast, compared with the elastic arteries, the medium-sized muscular
252 arteries are barely affected by age and less distensible.^{22,23} Moreover, the stiffness of medium-sized
253 muscular arteries is modulated by the vasomotor tone depending on either the endothelial function,
254 sympathetic nervous system,^{24,25} or renin–angiotensin system.²⁶ Moreover, Wohlfahrt et al²⁷
255 reported that the stiffness of the lower-extremity artery, which was determined using PWV from the
256 femoral artery to dorsal pedal/posterior tibial arteries, was affected to a lesser extent by age and
257 cardiovascular risk factors than aortic stiffness (cfPWV); further, increased ankle systolic blood
258 pressure was associated with the stiffness of the lower-extremity artery in a random sample from
259 the Czech population. Because PWV is dependent on blood pressure, these associations may be
260 observed; our taBETA was less dependent on blood pressure. However, the measurement
261 segment of taBETA is a functional medium-sized muscular artery, which is modulated by the
262 vasomotor tone, particularly in young age. The association between blood pressure and stiffness of
263 the lower-extremity artery, which was calculated by the stiffness parameter β theory, was observed
264 in the present study, suggesting that blood pressure is one of the important factors associated with
265 the stiffness of medium-sized muscular arteries.

266 Data regarding aging of the lower-extremity arteries are discrepant: in some studies,^{23,28} no
267 increase in stiffness with age was observed, whereas in other studies,^{29,30} stiffness was found to
268 increase with age. This discrepancy may be explained by the minor effect of age on the stiffness of
269 the lower-extremity arteries and by the different methods of arterial stiffness measurement.

270 The stiffness of the muscle artery (taBETA) did not differ between the healthy subjects and patients
271 with CAD in the present study. By contrast, Yamamoto et al¹⁴ reported lower taBETA in their healthy
272 group (14.10 ± 4.14) than that in our healthy subjects (21.27 ± 6.68), and it was higher in their
273 patients with atherosclerosis (25.45 ± 22.31) than in our patients with CAD (21.14 ± 8.36). These
274 discrepancies may be explained by the age and sex differences between both studies, considering
275 that the age of the healthy subjects and patients were 30.9 vs. 54.0 and 72.0 vs. 64.1 years and the

276 proportion of men were 100% vs. 39% and 84% vs. 76% (Yamamoto et al's data vs. our data),
277 respectively. Therefore, although taBETA may be lower in younger healthy subjects aged
278 approximately 30 years, the changes in the stiffness of muscular artery (taBETA) appear to be
279 extremely small in elderly individuals aged >50 years who are predominantly at risk of
280 atherosclerosis.

281 Furthermore, haBETA was more strongly correlated with htBETA ($r = 0.78$) than with taBETA (r
282 $=0.46$) in healthy subjects (Figure 1), and the multiple regression analysis revealed that haBETA
283 can be almost precisely estimated using htBETA and taBETA (Figure 4). However, these
284 relationships were weakened in patients with CAD (Figure 4). Furthermore, the proportion of the
285 variance of htBETA to haBETA was greater and that of taBETA to haBETA was smaller in healthy
286 subjects compared with the proportions in patients with CAD (Figure 3). Therefore, the
287 nonuniformity of the arterial system between elastic and medium-sized muscular arteries would
288 disappear in patients with CAD, which is typically observed in healthy young subjects.

289 Previously, we have demonstrated that CAVI, which includes the coefficients "a" and "b" on the
290 haBETA formula, was significantly correlated with the regional stiffness parameter β of the
291 ascending and descending aorta calculated from electrocardiogram-gated multidetector row
292 computed tomography and that the ratio of the thoracic aorta pulse wave propagation time (heart–
293 thigh) to the entire pulse wave propagation time from the heart to the ankle was large, which may
294 substantially impact the entire PWV (heart–ankle).³¹ In addition, Wohlfahrt et al.³² reported that
295 cfPWV was positively correlated with carotid–ankle PWV, and the addition of thigh–ankle PWV to
296 cfPWV decreased the association with age, which can only be explained by the minor effect of this
297 factor on the arterial stiffness of medium-sized extremity muscular artery. Accordingly, these studies
298 suggested that CAVI (haBETA) shows the highest dependence on the stiffness of the central artery,
299 such as thoracic aortas, and age is a major confounder of this stiffness.

300 Recently, Fico et al.³³ determined cfPWV using an automatic vascular screening device (VP-1000
301 Plus, Omron Healthcare, Kyoto, Japan), and the heart–thigh PWV (htPWV) was determined with
302 the same device in our study of 50 healthy subjects (18–79 years old). The mean values of cfPWV

303 (713 ± 145 cm/s) and htPWV (699 ± 150) did not differ ($p = 0.43$), and these correlations were high
304 ($r = 0.64$, $p < 0.001$). The regression line was derived from the line of identity in the Bland–Altman
305 plot. Further, these results suggested that htBETA has good potential for assessing arterial stiffness
306 in the clinical setting in comparison to cfPWV.

307 The comparison of the segmental β s shows that htBETA, but not taBETA, was significantly higher
308 in patients with CAD than in healthy subjects (Table 3). However, the ROC curve analysis showed
309 that htBETA did not improve the diagnostic power for CAD compared with haBETA, which
310 comprises htBETA and taBETA. These data may be extremely important because the lengthening
311 of the measurement site from the heart–thigh distance (elastic artery) to the heart–ankle distance
312 (elastic artery plus medium-sized muscular artery) does not decrease the diagnostic power for
313 middle-aged patients with CAD.

314 ***Study limitations***

315 Several healthy subjects were using antihypertensive (10%), hypoglycemic (2.2%), and
316 hypolipidemic (6.7%) drugs, and patients with CAD were using some medications, which may have
317 influenced our results.

318 Moreover, although coronary arteriography or computed tomography of the coronary artery was not
319 performed, the ischemic change in the electrocardiogram at rest for all healthy subjects was not
320 observed. For comparing each β between healthy subjects and patients with CAD, both study
321 populations were heterogeneous. However, the characteristics of healthy subjects appear to
322 represent the status of the subjects undergoing general medical examinations in Japan.

323 **Conclusion**

324 The stiffness of the medium-sized thigh–ankle artery was three times greater than the elastic heart–
325 ankle artery. Its stiffness was constant and that of the elastic aorta correlated with age. It was
326 possible to estimate two-thirds of the components of the stiffness of the heart–ankle artery using the
327 stiffness of the heart–thigh artery. The ROC curve analysis revealed that the stiffness of the heart–

328 ankle artery could be replaced by that of the heart–thigh artery, prolonging the measurement
329 segment without affecting the diagnostic power for CAD.

330 Disclosure

331 The authors have no conflicts of interest in this manuscript.

332 References

- 333 1. Shokawa T, Imazu M, Yamamoto H, et al. Pulse wave velocity predicts cardiovascular
334 mortality: findings from the Hawaii-Los Angeles-Hiroshima study. *Circ J*. 2005;69(3):259–264.
- 335 2. Willum-Hansen T, Staessen JA, Torp-Pedersen C, et al. Prognostic value of aortic pulse wave
336 velocity as index of arterial stiffness in the general population. *Circulation*. 2006;113(5):664–
337 670.
- 338 3. Pannier B, Guérin AP, Marchais SJ, Safar ME, London GM. Stiffness of capacitive and conduit
339 arteries: prognostic significance for end-stage renal disease patients. *Hypertension*.
340 2005;45(4):592–596.
- 341 4. Laurent S, Cockcroft J, Van Bortel L, et al; European Network for Non-invasive Investigation of
342 Large Arteries. Expert consensus document on arterial stiffness: methodological issues and
343 clinical applications. *Eur Heart J*. 2006;27(21):2588–2605.
- 344 5. Bramwell JC, Hill AV. Velocity of transmission of the pulse and elasticity of arteries. *Lancet*.
345 1922;1:891.
- 346 6. Spronck B, Heusinkveld MH, Vanmolkot FH, et al. Pressure-dependence of arterial stiffness:
347 potential clinical implications. *J Hypertens*. 2015;33(2):330–338.
- 348 7. Hayashi K, Handa H, Nagasawa S, Okumura A, Moritake K. Stiffness and elastic behavior of
349 human intracranial and extracranial arteries. *J Biomech*. 1980;13(2):175–184.
- 350 8. Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressure-independent arterial wall
351 stiffness parameter; cardio-ankle vascular index (CAVI). *J Atheroscler Thromb*.
352 2006;13(2):101–107.

- 353 9. Takahashi K, Yamamoto T, Tsuda S, et al. Coefficients in the CAVI equation and the
354 comparison between CAVI with and without the coefficients using clinical data. *J Atheroscler*
355 *Thromb.* 2019;26(5):465–475.
- 356 10. Hayashi K, Yamamoto T, Takahara A, Shirai K. Clinical assessment of arterial stiffness with
357 cardio-ankle vascular index: theory and applications. *J Hypertens.* 2015;33(9):1742–1757.
- 358 11. Hasegawa M, Arai C. Clinical estimation of vascular elastic function and practical application.
359 *Connective Tissue.* 1995;27(2):149–157.
- 360 12. Hickson SS, Butlin M, Broad J, Avolio AP, Wilkinson IB, McEniery CM. Validity and
361 repeatability of the Vicorder apparatus: a comparison with the SphygmoCor device. *Hypertens*
362 *Res.* 2009;32(12):1079–1085.
- 363 13. Butlin M, Qasem A, Battista F, Bozec E, et al. Carotid-femoral pulse wave velocity assessment
364 using novel cuff-based techniques: comparison with tonometric measurement. *J Hypertens.*
365 2013;31(11):2237–2243.
- 366 14. Yamamoto T, Shimizu K, Takahashi M, Tatsuno I, Shirai K. The effect of nitroglycerin on
367 arterial stiffness of the aorta and the femoral-tibial arteries. *J Atheroscler Thromb.*
368 2017;24(10):1048–1057.
- 369 15. Yonezawa Y, Horinaka S, Shirakawa C, Kogure Y. Estimated glomerular filtration ratio is a
370 better index than creatinine clearance (Cockcroft-Gault) for predicting the prevalence of atrial
371 fibrillation in the general Japanese population. *Hypertens Res.* 2018;41(6):451–459.
- 372 16. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the
373 Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the
374 American College of Cardiology/American Heart Association Task Force on Clinical Practice
375 Guidelines. *Circulation.* 2017;135(12):e726–e779.
- 376 17. Horinaka S, Yabe A, Yagi H, et al. Comparison of atherosclerotic indicators between cardio
377 ankle vascular index and brachial ankle pulse wave velocity. *Angiology.* 2009;60(4):468–476.
- 378 18. Obuchowski NA, Lieber ML, Wians FH Jr. ROC curves in clinical chemistry: uses, misuses,
379 and possible solutions. *Clin Chem.* 2004;50(7):1118–1125.

- 380 19. Nye ER. The effect of blood pressure alteration on the pulse wave velocity. *Br Heart J*.
381 1964;26(2):261–265.
- 382 20. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating
383 characteristic (ROC) curve. *Radiology*. 1982;143(1):29–36.
- 384 21. Valchopoulos C, Nichols WW, O'Rourke MF. *McDonald's Blood Flow in Arteries: Theoretical,*
385 *Experimental and Clinical Principles*. 6th ed. London: CRC Press; 2011.
- 386 22. van der Heijden-Spek JJ, Staessen JA, Fagard RH, Hoeks AP, Boudier HA, van Bortel LM.
387 Effect of age on brachial artery wall properties differs from the aorta and is gender dependent:
388 a population study. *Hypertension*. 2000;35(2):637–642.
- 389 23. Boutouyrie P, Laurent S, Benetos A, Girerd XJ, Hoeks AP, Safar ME. Opposing effects of
390 ageing on distal and proximal large arteries in hypertensives. *J Hypertens*. 1992;10(6):S87–
391 S91.
- 392 24. Boutouyrie P, Lacolley P, Girerd X, Beck L, Safar M, Laurent S. Sympathetic activation
393 decreases medium-sized arterial compliance in humans. *Am J Physiol*. 1994;267(4 Pt
394 2):H1368–H1376.
- 395 25. Giannattasio C, Failla M, Lucchina S, et al. Arterial stiffening influence of sympathetic nerve
396 activity: evidence from hand transplantation in humans. *Hypertension*. 2005;45(4):608–611.
- 397 26. Giannattasio C, Failla M, Stella ML, et al. Angiotensin-converting enzyme inhibition and radial
398 artery compliance in patients with congestive heart failure. *Hypertension*. 1995;26(3):491–496.
- 399 27. Wohlfahrt P, Krajčoviechová A, Seidlerová J, et al. Lower-extremity arterial stiffness vs. aortic
400 stiffness in the general population. *Hypertens Res*. 2013;36(8):718–724.
- 401 28. Benetos A, Laurent S, Hoeks AP, Boutouyrie PH, Safar ME. Arterial alterations with aging and
402 high blood pressure. A noninvasive study of carotid and femoral arteries. *Arterioscler Thromb*.
403 1993;13(1):90–97.
- 404 29. Lo CS, Relf IR, Myers KA, Wahlqvist ML. Doppler ultrasound recognition of preclinical changes
405 in arterial wall in diabetic subjects: compliance and pulse-wave damping. *Diabetes Care*.
406 1986;9(1):27–31.

- 407 30. Blacher J, Demuth K, Guerin AP, Safar ME, Moatti N, London GM. Influence of biochemical
408 alterations on arterial stiffness in patients with end-stage renal disease. *Arterioscler Thromb*
409 *Vasc Biol.* 1998;18(4):535–541.
- 410 31. Horinaka S, Yagi H, Ishimura K, et al. Cardio-ankle vascular index (CAVI) correlates with aortic
411 stiffness in the thoracic aorta using ECG-gated multi-detector row computed tomography.
412 *Atherosclerosis.* 2014;235(1):239–245.
- 413 32. Wohlfahrt P, Krajčoviechová A, Seidlerová J, et al. Arterial stiffness parameters: how do they
414 differ? *Atherosclerosis.* 2013;231(2):359–364.
- 415 33. Fico BG, Gourley DD, Wooten SV, Tanaka H. Heart-thigh cuff pulse wave velocity: A novel
416 nontechnical measure of arterial stiffness. *Am J Hypertens.* 2019;32(11):1051–1053.
417

418 **Figure 1** Correlation between each segmental β in healthy subjects.
419 haBETA, heart–ankle β ; htBETA, heart–thigh β ; taBETA, thigh–ankle β ; r, correlation coefficient

420 **Figure 2** Correlation between each segmental β in patients with coronary artery disease.

421 **Figure 3** Principal component analysis in healthy subjects and patients with coronary artery disease.
422 Component 1: horizontal (relationship between htBETA and haBETA)
423 Component 2: vertical (relationship between taBETA and haBETA)
424 haBETA, heart–ankle β ; htBETA, heart–thigh β ; taBETA, thigh–ankle β

425 **Figure 4** Multiple linear regression model for haBETA with htBETA and taBETA in healthy subjects
426 and patients with coronary artery disease.
427 haBETA, heart–ankle β ; htBETA, heart–thigh β ; taBETA, thigh–ankle β

428 **Figure 5** Receiver operating characteristic (ROC) curves of haBETA, htBETA, and taBETA in
429 coronary artery disease (CAD).
430 — haBETA: cutoff value 9.20, sensitivity 80.5, specificity 63.3%
431 — htBETA: cutoff value 7.72, sensitivity 75.6, specificity 68.9%
432 — taBETA: cutoff value 21.0, sensitivity 65.6, specificity 45.6%

433 Each arrow indicates the optimal threshold (cutoff value) of haBETA, htBETA, and taBETA for the
434 discernment of the presence of CAD, respectively.

435 The area under the ROC curve (AUC \pm SE) of haBETA, htBETA, and taBETA were 0.731 ± 0.046
436 ($p < 0.01$), 0.757 ± 0.043 ($p < 0.01$), and 0.493 ± 0.054 ($p = 0.49$), respectively.
437 SE, standard error; haBETA, heart–ankle β ; htBETA, heart–thigh β ; taBETA, thigh–ankle β .